Figure 5: Blockage of SNAT2-induced hepatic mTORC1/S6K activation improves hypertriglyceridemia. | Nature Communications

Figure 5: Blockage of SNAT2-induced hepatic mTORC1/S6K activation improves hypertriglyceridemia.

From: A hepatic amino acid/mTOR/S6K-dependent signalling pathway modulates systemic lipid metabolism via neuronal signals

Figure 5

(a–d) Mixed adenoviruses, that is, double-dose LacZ-adenovirus (ZZ), LacZ plus SNAT2 (ZS) and SNAT2 plus DN-S6K (SDN) adenoviruses, were administered to C57BL/6 mice. (a) Immunoblotting of liver extracts with anti-SNAT2 or p70-S6K antibodies. (b) SNAT2 mRNA expressions in the liver were analysed by RT–PCR (n=5–6). (c) Immunoblotting of liver extracts with anti-phospho-S6 or S6 antibodies. (d) Serum TG levels were measured on day 5 after adenovirus administration (n=4–6). The representative images derived from at least two experiments were displayed (a and c). Data are presented as means±s.d. **P<0.01 by the unpaired t-test. NS, not significant.

Back to article page